IN2014DN10404A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10404A
IN2014DN10404A IN10404DEN2014A IN2014DN10404A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A IN 10404DEN2014 A IN10404DEN2014 A IN 10404DEN2014A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A
Authority
IN
India
Prior art keywords
pde7
addictions
phosphodiesterase
directed
disclosure
Prior art date
Application number
Other languages
English (en)
Inventor
Gregory A Demopulos
George A Gaitanaris
Roberto Ciccocioppo
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of IN2014DN10404A publication Critical patent/IN2014DN10404A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10404DEN2014 2012-05-07 2013-05-07 IN2014DN10404A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10404A true IN2014DN10404A (enExample) 2015-08-14

Family

ID=49624481

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10404DEN2014 IN2014DN10404A (enExample) 2012-05-07 2013-05-07

Country Status (10)

Country Link
EP (1) EP2846805B1 (enExample)
JP (1) JP2015521177A (enExample)
CN (3) CN104768556A (enExample)
AU (1) AU2013266793B2 (enExample)
CA (1) CA2871151C (enExample)
IN (1) IN2014DN10404A (enExample)
PL (1) PL2846805T3 (enExample)
RS (1) RS58381B1 (enExample)
SI (1) SI2846805T1 (enExample)
WO (1) WO2013176877A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038567A (zh) 2010-11-08 2016-10-26 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN109937038A (zh) * 2016-08-26 2019-06-25 田边三菱制药株式会社 双环式含氮杂环化合物
WO2023243659A1 (ja) * 2022-06-15 2023-12-21 真一 松本 線条体ストリオソームのドパミンd1シグナルを標的とした強迫性障害の薬物療法
US20260048059A1 (en) 2022-08-18 2026-02-19 Klaus Wirth Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004040A1 (ja) * 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Pde7阻害作用を有するチエノピラゾール誘導体
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
CA2623072A1 (en) * 2005-09-26 2007-04-05 Avigen, Inc. Use of ibudilast for treating drug and behavioral addictions
JP5580192B2 (ja) * 2007-03-27 2014-08-27 オメロス コーポレーション 運動障害の処置のためのpde7インヒビターの使用
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
CN106038567A (zh) * 2010-11-08 2016-10-26 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍

Also Published As

Publication number Publication date
EP2846805A2 (en) 2015-03-18
CA2871151A1 (en) 2013-11-28
CN114984229A (zh) 2022-09-02
WO2013176877A3 (en) 2015-06-18
CA2871151C (en) 2019-03-26
JP2015521177A (ja) 2015-07-27
WO2013176877A2 (en) 2013-11-28
CN112168972A (zh) 2021-01-05
CN104768556A (zh) 2015-07-08
SI2846805T1 (sl) 2019-04-30
EP2846805A4 (en) 2016-08-10
AU2013266793A1 (en) 2014-11-27
PL2846805T3 (pl) 2019-05-31
RS58381B1 (sr) 2019-04-30
EP2846805B1 (en) 2018-11-21
AU2013266793B2 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
MX389018B (es) Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PL2825161T3 (pl) Inhibitory ludzkiej ezh2 i sposoby ich zastosowania
IL245042A0 (en) Treatment with proton tyrosine kinase inhibitors and immunotherapy
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
IN2014CN04014A (enExample)
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PH12014500925A1 (en) Therapeutic combinations and methods of treating melanoma
IN2014DN10404A (enExample)
PL2780025T3 (pl) Zastosowanie ekstraktów z wiązówki (Filipendula) do leczenia i profilaktyki przewlekłych stanów bólowych
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MY200803A (en) Mpo inhibitors for use in medicine
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
WO2012097121A9 (en) Specific nnos inhibitors for the therapy and prevention of human melanoma
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
PT2790687T (pt) Moduladores de trpc4 para uso no tratamento ou prevenção da dor
LT2846805T (lt) Priklausomybių ir impulsų kontrolės sutrikimų gydymas, panaudojant pde7 inhibitorius
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
HK1223014B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.
AU2013101402A4 (en) Timber treatment formulations and methods of use